ABCC1 and pancreatic neoplasm: Clinical researches have confirmed that high expression of MDR1 and MRP1 could result in GEM resistance, and that up-regulation of MDR1 and MRP1 in pancreatic tumors could contribute to a generally poor treatment response and a shorter postoperative survival time (23–26).